Medical Industry Feature

Fibrodysplasia ossificans progressiva (FOP) is a severely disabling myopathy in which extraskeletal bone forms and accumulates over time within muscles and soft tissues.^1,2 Here’s what we know so far…

Because standard-dose vaccines usually produce only modest immunogenic responses in people age 65 years and older, the Advisory Committe…

Immune imprinting refers to how the immune system's first encounter with a virus, such as influenza, leaves a lasting imprint that shapes future immune responses.^1,2 However, influenza vaccines may a…

Listen to Dr. Eric Ritchey explain how he introduces MiSight^® 1 day to parents—highlighting its safety, comfort, and dual benefits—and emphasizes the impo…

In this short video, Dr. Shelia Morrison explains how she introduces parents to myopia management by emphasizing that today's treatment options—like MiS…

Dr. Ariel Cerenzie shares quick tips on how she communicates the urgency of myopia progression to parents and introduces MiSight^® 1 day as a proactive …

In this short video, Dr. Ashley Tucker shares how she talks to parents about myopia management, emphasizing that myopia is more than just blur…

Mateo Mejia Saldarriaga, M.D., a hematologist/oncologist at NewYork-Presbyterian and Weill Cornell Medicine, explains how he and his team conducted a re…

Tamatha Fenster, M.D., M.S., gynecologic surgeon at NewYork-Presbyterian and director of innovation and technology at The Weill Cornell Medicine Fibroid a…

On this episode of Advances in Care, host Erin Welsh talks to Dr. Andrew Goldstone, pediatric cardiac surgeon at NewYork-Presbyterian and Columbia, abou…

As the array of novel therapies for plaque psoriasis expands, a strategy to navigate treatment options is to focus on the sp…

Guess what? The CDC's Advisory Committee on Immunization Practices had a unanimous vote in favor of a preferential recommendation of vaccines for the cool adults who are 65 and older—one of these opt…

For children with rheumatic diseases, early diagnosis, personalized care, and multidisciplinary collaboration are critical for optimal long-term management. Join…

On this episode of Advances in Care, host Erin Welsh explores the story behind the GUARDIAN study, w…

Biosimilars have greatly impacted the US healthcare system over the last decade, creating cost savings and increasing access for patients.^1,2 However, a…

Although acute lymphoblastic leukemia (ALL) is a relatively rare disease with fewer than 7,000 people diagnosed each…

Glioblastomas are fast, aggressive, and resistant to many standard therapies. Dr. Lauren Schaff, a neuro-oncologist at Memorial Sloan Kettering Cancer Center, expla…

The FDA approval of vorasidenib marks a new era for mutant isocitrate dehydrogenase (mIDH) gliomas. Approved in 2024 for grade 2 tumors after surgery, it doubled pr…

Defined by the production of 2-hydroxyglutarate, mutant isocitrate dehydrogenase (mIDH) gliomas are diffuse, slow-growing tumors. Managing these tumors requires per…

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a complex immune-mediated condition affecting the peripheral nervous system. Join Dr. Hans Katzb…